Higher risk of kidney graft failure in the presence of anti-angiotensin II Type-1 receptor antibodies

M. Taniguchi, L. M. Rebellato, J. Cai, J. Hopfield, K. P. Briley, C. E. Haisch, P. G. Catrou, P. Bolin, K. Parker, W. T. Kendrick, S. A. Kendrick, R. C. Harland, P. I. Terasaki

Research output: Contribution to journalArticle

109 Citations (Scopus)

Abstract

Reports have associated non-HLA antibodies, specifically those against angiotensin II type-1 receptor (AT1R), with antibody-mediated kidney graft rejection. However, association of anti-AT1R with graft failure had not been demonstrated. We tested anti-AT1R and donor-specific HLA antibodies (DSA) in pre- and posttransplant sera from 351 consecutive kidney recipients: 134 with biopsy-proven rejection and/or lesions (abnormal biopsy group [ABG]) and 217 control group (CG) patients. The ABG's rate of anti-AT1R was significantly higher than the CG's (18% vs. 6%, p < 0.001). Moreover, 79% of ABG patients with anti-AT1R lost their grafts (vs. 0%, CG), anti-AT1R levels in 58% of those failed grafts increasing posttransplant. With anti-AT1R detectable before DSA, time to graft failure was 31 months - but 63 months with DSA detectable before anti-AT1R. Patients with both anti-AT1R and DSA had lower graft survival than those with DSA alone (log-rank p = 0.007). Multivariate analysis showed that de novo anti-AT1R was an independent predictor of graft failure in the ABG, alone (HR: 6.6), and in the entire population (HR: 5.4). In conclusion, this study found significant association of anti-AT1R with graft failure. Further study is needed to establish causality between anti-AT1R and graft failure and, thus, the importance of routine anti-AT1R monitoring and therapeutic targeting. This study examines the association of non-HLA antibodies against angiotensin II type 1 receptor with kidney allograft failure, showing the higher frequency of those antibodies in biopsy-abnormal patients and also showing the independent association of de novo antibodies with graft failure. See related paper by Giral et al (page 2567) and editorial by Tinckam and Campbell (page 2515).

Original languageEnglish (US)
Pages (from-to)2577-2589
Number of pages13
JournalAmerican Journal of Transplantation
Volume13
Issue number10
DOIs
StatePublished - Oct 1 2013
Externally publishedYes

Fingerprint

Angiotensin Type 1 Receptor
Renal Insufficiency
Transplants
Antibodies
Tissue Donors
Biopsy
Kidney
Control Groups
Graft Rejection
Graft Survival
Causality
Allografts

Keywords

  • Angiotensin II type-1 receptor antibodies
  • AT1R
  • DSA
  • kidney transplantation
  • rejection

ASJC Scopus subject areas

  • Immunology and Allergy
  • Transplantation
  • Pharmacology (medical)

Cite this

Taniguchi, M., Rebellato, L. M., Cai, J., Hopfield, J., Briley, K. P., Haisch, C. E., ... Terasaki, P. I. (2013). Higher risk of kidney graft failure in the presence of anti-angiotensin II Type-1 receptor antibodies. American Journal of Transplantation, 13(10), 2577-2589. https://doi.org/10.1111/ajt.12395

Higher risk of kidney graft failure in the presence of anti-angiotensin II Type-1 receptor antibodies. / Taniguchi, M.; Rebellato, L. M.; Cai, J.; Hopfield, J.; Briley, K. P.; Haisch, C. E.; Catrou, P. G.; Bolin, P.; Parker, K.; Kendrick, W. T.; Kendrick, S. A.; Harland, R. C.; Terasaki, P. I.

In: American Journal of Transplantation, Vol. 13, No. 10, 01.10.2013, p. 2577-2589.

Research output: Contribution to journalArticle

Taniguchi, M, Rebellato, LM, Cai, J, Hopfield, J, Briley, KP, Haisch, CE, Catrou, PG, Bolin, P, Parker, K, Kendrick, WT, Kendrick, SA, Harland, RC & Terasaki, PI 2013, 'Higher risk of kidney graft failure in the presence of anti-angiotensin II Type-1 receptor antibodies', American Journal of Transplantation, vol. 13, no. 10, pp. 2577-2589. https://doi.org/10.1111/ajt.12395
Taniguchi, M. ; Rebellato, L. M. ; Cai, J. ; Hopfield, J. ; Briley, K. P. ; Haisch, C. E. ; Catrou, P. G. ; Bolin, P. ; Parker, K. ; Kendrick, W. T. ; Kendrick, S. A. ; Harland, R. C. ; Terasaki, P. I. / Higher risk of kidney graft failure in the presence of anti-angiotensin II Type-1 receptor antibodies. In: American Journal of Transplantation. 2013 ; Vol. 13, No. 10. pp. 2577-2589.
@article{fc80fb90dd054a72b3b53590b54a53d5,
title = "Higher risk of kidney graft failure in the presence of anti-angiotensin II Type-1 receptor antibodies",
abstract = "Reports have associated non-HLA antibodies, specifically those against angiotensin II type-1 receptor (AT1R), with antibody-mediated kidney graft rejection. However, association of anti-AT1R with graft failure had not been demonstrated. We tested anti-AT1R and donor-specific HLA antibodies (DSA) in pre- and posttransplant sera from 351 consecutive kidney recipients: 134 with biopsy-proven rejection and/or lesions (abnormal biopsy group [ABG]) and 217 control group (CG) patients. The ABG's rate of anti-AT1R was significantly higher than the CG's (18{\%} vs. 6{\%}, p < 0.001). Moreover, 79{\%} of ABG patients with anti-AT1R lost their grafts (vs. 0{\%}, CG), anti-AT1R levels in 58{\%} of those failed grafts increasing posttransplant. With anti-AT1R detectable before DSA, time to graft failure was 31 months - but 63 months with DSA detectable before anti-AT1R. Patients with both anti-AT1R and DSA had lower graft survival than those with DSA alone (log-rank p = 0.007). Multivariate analysis showed that de novo anti-AT1R was an independent predictor of graft failure in the ABG, alone (HR: 6.6), and in the entire population (HR: 5.4). In conclusion, this study found significant association of anti-AT1R with graft failure. Further study is needed to establish causality between anti-AT1R and graft failure and, thus, the importance of routine anti-AT1R monitoring and therapeutic targeting. This study examines the association of non-HLA antibodies against angiotensin II type 1 receptor with kidney allograft failure, showing the higher frequency of those antibodies in biopsy-abnormal patients and also showing the independent association of de novo antibodies with graft failure. See related paper by Giral et al (page 2567) and editorial by Tinckam and Campbell (page 2515).",
keywords = "Angiotensin II type-1 receptor antibodies, AT1R, DSA, kidney transplantation, rejection",
author = "M. Taniguchi and Rebellato, {L. M.} and J. Cai and J. Hopfield and Briley, {K. P.} and Haisch, {C. E.} and Catrou, {P. G.} and P. Bolin and K. Parker and Kendrick, {W. T.} and Kendrick, {S. A.} and Harland, {R. C.} and Terasaki, {P. I.}",
year = "2013",
month = "10",
day = "1",
doi = "10.1111/ajt.12395",
language = "English (US)",
volume = "13",
pages = "2577--2589",
journal = "American Journal of Transplantation",
issn = "1600-6135",
publisher = "Wiley-Blackwell",
number = "10",

}

TY - JOUR

T1 - Higher risk of kidney graft failure in the presence of anti-angiotensin II Type-1 receptor antibodies

AU - Taniguchi, M.

AU - Rebellato, L. M.

AU - Cai, J.

AU - Hopfield, J.

AU - Briley, K. P.

AU - Haisch, C. E.

AU - Catrou, P. G.

AU - Bolin, P.

AU - Parker, K.

AU - Kendrick, W. T.

AU - Kendrick, S. A.

AU - Harland, R. C.

AU - Terasaki, P. I.

PY - 2013/10/1

Y1 - 2013/10/1

N2 - Reports have associated non-HLA antibodies, specifically those against angiotensin II type-1 receptor (AT1R), with antibody-mediated kidney graft rejection. However, association of anti-AT1R with graft failure had not been demonstrated. We tested anti-AT1R and donor-specific HLA antibodies (DSA) in pre- and posttransplant sera from 351 consecutive kidney recipients: 134 with biopsy-proven rejection and/or lesions (abnormal biopsy group [ABG]) and 217 control group (CG) patients. The ABG's rate of anti-AT1R was significantly higher than the CG's (18% vs. 6%, p < 0.001). Moreover, 79% of ABG patients with anti-AT1R lost their grafts (vs. 0%, CG), anti-AT1R levels in 58% of those failed grafts increasing posttransplant. With anti-AT1R detectable before DSA, time to graft failure was 31 months - but 63 months with DSA detectable before anti-AT1R. Patients with both anti-AT1R and DSA had lower graft survival than those with DSA alone (log-rank p = 0.007). Multivariate analysis showed that de novo anti-AT1R was an independent predictor of graft failure in the ABG, alone (HR: 6.6), and in the entire population (HR: 5.4). In conclusion, this study found significant association of anti-AT1R with graft failure. Further study is needed to establish causality between anti-AT1R and graft failure and, thus, the importance of routine anti-AT1R monitoring and therapeutic targeting. This study examines the association of non-HLA antibodies against angiotensin II type 1 receptor with kidney allograft failure, showing the higher frequency of those antibodies in biopsy-abnormal patients and also showing the independent association of de novo antibodies with graft failure. See related paper by Giral et al (page 2567) and editorial by Tinckam and Campbell (page 2515).

AB - Reports have associated non-HLA antibodies, specifically those against angiotensin II type-1 receptor (AT1R), with antibody-mediated kidney graft rejection. However, association of anti-AT1R with graft failure had not been demonstrated. We tested anti-AT1R and donor-specific HLA antibodies (DSA) in pre- and posttransplant sera from 351 consecutive kidney recipients: 134 with biopsy-proven rejection and/or lesions (abnormal biopsy group [ABG]) and 217 control group (CG) patients. The ABG's rate of anti-AT1R was significantly higher than the CG's (18% vs. 6%, p < 0.001). Moreover, 79% of ABG patients with anti-AT1R lost their grafts (vs. 0%, CG), anti-AT1R levels in 58% of those failed grafts increasing posttransplant. With anti-AT1R detectable before DSA, time to graft failure was 31 months - but 63 months with DSA detectable before anti-AT1R. Patients with both anti-AT1R and DSA had lower graft survival than those with DSA alone (log-rank p = 0.007). Multivariate analysis showed that de novo anti-AT1R was an independent predictor of graft failure in the ABG, alone (HR: 6.6), and in the entire population (HR: 5.4). In conclusion, this study found significant association of anti-AT1R with graft failure. Further study is needed to establish causality between anti-AT1R and graft failure and, thus, the importance of routine anti-AT1R monitoring and therapeutic targeting. This study examines the association of non-HLA antibodies against angiotensin II type 1 receptor with kidney allograft failure, showing the higher frequency of those antibodies in biopsy-abnormal patients and also showing the independent association of de novo antibodies with graft failure. See related paper by Giral et al (page 2567) and editorial by Tinckam and Campbell (page 2515).

KW - Angiotensin II type-1 receptor antibodies

KW - AT1R

KW - DSA

KW - kidney transplantation

KW - rejection

UR - http://www.scopus.com/inward/record.url?scp=84884907041&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84884907041&partnerID=8YFLogxK

U2 - 10.1111/ajt.12395

DO - 10.1111/ajt.12395

M3 - Article

C2 - 23941128

AN - SCOPUS:84884907041

VL - 13

SP - 2577

EP - 2589

JO - American Journal of Transplantation

JF - American Journal of Transplantation

SN - 1600-6135

IS - 10

ER -